What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...Myeloma News
Powered By:
- FDA Grants Accelerated Approval To Melphalan Flufenamide For Relapsed Or Refractory Multiple Myeloma
- FDA Approves Oncopeptides’ PEPAXTO® ( Melphalan Flufenamide) For Patients With Relapsed Or Refractory Multiple Myeloma
- The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
- CAR T-cell Therapy Generates Lasting Remissions In Patients With Multiple Myeloma
- Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
- New Recommendations Aim To Eliminate Racial Bias In Myeloma Trials
- Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
- Cancer Drug Shows Potent Activity in the Lab Against SARS-CoV-2, Including New Variants
- Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma
- FDA Approves Karyopharm’s Xpovio To Treat Multiple Myeloma After At Least One Prior Therapy